
        <!DOCTYPE html>
        <html>
        <head>
            <title>Immunovant Inc. (IMVT) - Articles</title>
            <meta name="viewport" content="width=device-width, initial-scale=1.0">
            <style>
                :root {
                    --primary-color: #000000;
                    --secondary-color: #666666;
                    --accent-color: #d5001c;
                    --text-color: #2c3e50;
                    --border-color: #e0e0e0;
                    --hover-color: #f8f9fa;
                }
                
                body { 
                    font-family: "Porsche Next", "Segoe UI", Arial, sans-serif;
                    margin: 0;
                    padding: 0;
                    color: var(--text-color);
                    background-color: #f5f6fa;
                    line-height: 1.6;
                }
                
                .header {
                    background: linear-gradient(135deg, #000 0%, #1a1a1a 100%);
                    padding: 25px 0;
                    box-shadow: 0 2px 10px rgba(0,0,0,0.2);
                    position: sticky;
                    top: 0;
                    z-index: 1000;
                    backdrop-filter: blur(10px);
                }
                
                .header::before {
                    content: '';
                    position: absolute;
                    top: 0;
                    left: 0;
                    right: 0;
                    bottom: 0;
                    background: radial-gradient(circle at 30% 50%, rgba(255,255,255,0.08) 0%, rgba(255,255,255,0) 70%);
                    pointer-events: none;
                }
                
                .header-content {
                    max-width: 1400px;
                    margin: 0 auto;
                    padding: 0 30px;
                    display: flex;
                    justify-content: space-between;
                    align-items: center;
                }
                
                .header-title {
                    font-size: 28px;
                    font-weight: 300;
                    color: #fff;
                    margin: 0;
                    letter-spacing: 1px;
                }
                
                .back-btn {
                    background: rgba(255,255,255,0.1);
                    border: 1px solid rgba(255,255,255,0.2);
                    padding: 10px 20px;
                    color: #fff;
                    text-decoration: none;
                    font-size: 14px;
                    border-radius: 4px;
                    transition: all 0.3s ease;
                    backdrop-filter: blur(5px);
                }
                
                .back-btn:hover {
                    background: rgba(255,255,255,0.2);
                    transform: translateY(-2px);
                }
                
                .container {
                    max-width: 1400px;
                    margin: 40px auto;
                    padding: 0 30px;
                }
                
                .stats-container {
                    display: grid;
                    grid-template-columns: repeat(auto-fit, minmax(250px, 1fr));
                    gap: 20px;
                    margin-bottom: 40px;
                }
                
                .stat-card {
                    background: #fff;
                    border-radius: 12px;
                    padding: 25px;
                    text-align: center;
                    box-shadow: 0 4px 20px rgba(0,0,0,0.08);
                    transition: transform 0.3s ease;
                }
                
                .stat-card:hover {
                    transform: translateY(-5px);
                }
                
                .stat-value {
                    font-size: 32px;
                    font-weight: 300;
                    color: var(--primary-color);
                    margin-bottom: 10px;
                }
                
                .stat-label {
                    font-size: 14px;
                    color: var(--secondary-color);
                    text-transform: uppercase;
                    letter-spacing: 1px;
                }
                
                .articles-grid {
                    display: grid;
                    grid-template-columns: repeat(auto-fill, minmax(400px, 1fr));
                    gap: 30px;
                    margin-top: 40px;
                }
                
                .article-card {
                    background: #fff;
                    border-radius: 12px;
                    overflow: hidden;
                    box-shadow: 0 4px 20px rgba(0,0,0,0.08);
                    transition: all 0.3s ease;
                }
                
                .article-card:hover {
                    transform: translateY(-5px);
                }
                
                .article-content {
                    padding: 25px;
                }
                
                .article-title {
                    font-size: 18px;
                    font-weight: 400;
                    margin: 0 0 15px;
                    line-height: 1.4;
                }
                
                .article-title a {
                    color: var(--primary-color);
                    text-decoration: none;
                    transition: color 0.2s ease;
                }
                
                .article-title a:hover {
                    color: var(--accent-color);
                }
                
                .article-meta {
                    display: flex;
                    align-items: center;
                    gap: 20px;
                    margin-bottom: 15px;
                    font-size: 14px;
                    color: var(--secondary-color);
                }
                
                .article-sentiment {
                    padding: 4px 12px;
                    border-radius: 20px;
                    font-weight: 500;
                    font-size: 14px;
                }
                
                .article-sentiment.positive {
                    background: rgba(40,167,69,0.1);
                    color: #28a745;
                }
                
                .article-sentiment.negative {
                    background: rgba(220,53,69,0.1);
                    color: #dc3545;
                }
                
                .article-sentiment.neutral {
                    background: rgba(108,117,125,0.1);
                    color: #6c757d;
                }
                
                .article-summary {
                    font-size: 14px;
                    color: var(--text-color);
                    line-height: 1.6;
                    margin-top: 15px;
                    opacity: 0.8;
                }
                
                @media (max-width: 768px) {
                    .header-content {
                        padding: 0 20px;
                    }
                    
                    .header-title {
                        font-size: 20px;
                    }
                    
                    .container {
                        padding: 0 20px;
                        margin: 20px auto;
                    }
                    
                    .articles-grid {
                        grid-template-columns: 1fr;
                        gap: 20px;
                    }
                    
                    .stat-card {
                        padding: 20px;
                    }
                    
                    .stat-value {
                        font-size: 28px;
                    }
                }
            </style>
        </head>
        <body>
            <div class="header">
                <div class="header-content">
                    <h1 class="header-title">Immunovant Inc. (IMVT)</h1>
                    <a href="sentiment_report_latest.html" class="back-btn">‚Üê Back to Dashboard</a>
                </div>
            </div>
            
            <div class="container">
                <div class="stats-container">
                    <div class="stat-card">
                        <div class="stat-value">10</div>
                        <div class="stat-label">Total Articles</div>
                    </div>
                    <div class="stat-card">
                        <div class="stat-value">8</div>
                        <div class="stat-label">Positive Articles</div>
                    </div>
                    <div class="stat-card">
                        <div class="stat-value">0</div>
                        <div class="stat-label">Negative Articles</div>
                    </div>
                    <div class="stat-card">
                        <div class="stat-value">0.60</div>
                        <div class="stat-label">Average Sentiment</div>
                    </div>
                </div>
                
                <div class="articles-grid">
        
                    <div class="article-card positive">
                        <div class="article-content">
                            <h3 class="article-title">
                                <a href="https://finnhub.io/api/news?id=af829db2615cc9079e662f38f3e7c8c9b28e19f91a45d7a00eae164bec2b165f" target="_blank" rel="noopener noreferrer">Why Immunovant Stock Blasted Higher Today</a>
                            </h3>
                            <div class="article-meta">
                                <span>2025-09-04</span>
                                <span>Yahoo</span>
                                <span class="article-sentiment positive">
                                    0.81
                                </span>
                            </div>
                            <div class="article-summary">The biotech looks as if it has a promising treatment for an autoimmune disorder....</div>
                        </div>
                    </div>
            
                    <div class="article-card positive">
                        <div class="article-content">
                            <h3 class="article-title">
                                <a href="https://finnhub.io/api/news?id=52a06b01417c899751a00252a089425d03665f0b696c5d7244feec5c3913c9d2" target="_blank" rel="noopener noreferrer">IMVT Stock Up 11% on Upbeat Batoclimab Hyperthyroidism Study Results</a>
                            </h3>
                            <div class="article-meta">
                                <span>2025-09-04</span>
                                <span>Yahoo</span>
                                <span class="article-sentiment positive">
                                    0.89
                                </span>
                            </div>
                            <div class="article-summary">Immunovant stock jumps 11% after new batoclimab study results showed durable thyroid hormone control in Graves' disease patients....</div>
                        </div>
                    </div>
            
                    <div class="article-card positive">
                        <div class="article-content">
                            <h3 class="article-title">
                                <a href="https://finnhub.io/api/news?id=f1f25f5903841705454a8276b51a8c46546d5336a1c1c631710683020a210148" target="_blank" rel="noopener noreferrer">Immunovant's New Data Shows Batoclimab's Potential to Replace Current Graves' Disease Options, Oppenheimer Says</a>
                            </h3>
                            <div class="article-meta">
                                <span>2025-09-04</span>
                                <span>Yahoo</span>
                                <span class="article-sentiment positive">
                                    0.88
                                </span>
                            </div>
                            <div class="article-summary">Immunovant's (IMVT) new batoclimab data show the treatment's potential to offer an alternative to cu...</div>
                        </div>
                    </div>
            
                    <div class="article-card positive">
                        <div class="article-content">
                            <h3 class="article-title">
                                <a href="https://finnhub.io/api/news?id=8c2b29008877acec7d003ff73e24394f8c64a1fd83a2f210cce64f237c8eb6c2" target="_blank" rel="noopener noreferrer">Immunovant Unveils Durability and Treatment-Free Six-month Remission Data with Potential to Change Treatment Paradigm for Uncontrolled Graves' Disease Patients</a>
                            </h3>
                            <div class="article-meta">
                                <span>2025-09-03</span>
                                <span>Yahoo</span>
                                <span class="article-sentiment positive">
                                    0.83
                                </span>
                            </div>
                            <div class="article-summary">First-ever potentially disease-modifying therapy for uncontrolled Graves‚Äô disease patientsOf 21 patients who entered the six-month off-treatment follow-up period, ~80% (17/21) demonstrated response, r...</div>
                        </div>
                    </div>
            
                    <div class="article-card positive">
                        <div class="article-content">
                            <h3 class="article-title">
                                <a href="https://finnhub.io/api/news?id=9cdf476133fbb0a55bc6a26f497ec9c354c5ffc8c2b621f1b0aa5a512fe4d3ec" target="_blank" rel="noopener noreferrer">Roivant Unveils Durability and Treatment-Free Six-month Remission Data with Potential to Change Treatment Paradigm for Uncontrolled Graves' Disease Patients</a>
                            </h3>
                            <div class="article-meta">
                                <span>2025-09-03</span>
                                <span>Yahoo</span>
                                <span class="article-sentiment positive">
                                    0.73
                                </span>
                            </div>
                            <div class="article-summary">First-ever potentially disease-modifying therapy for uncontrolled Graves‚Äô disease patientsOf 21 patients who entered the six-month off-treatment follow-up period, ~80% (17/21) demonstrated response, r...</div>
                        </div>
                    </div>
            
                    <div class="article-card positive">
                        <div class="article-content">
                            <h3 class="article-title">
                                <a href="https://finnhub.io/api/news?id=181ef55f9574e5fe9594aeefe2880521bb30c1d8c8d9a5899fa90c8d8be4588e" target="_blank" rel="noopener noreferrer">Immunovant Reports 'Encouraging' Data on Graves' Disease Treatment; Shares Rise</a>
                            </h3>
                            <div class="article-meta">
                                <span>2025-09-03</span>
                                <span>Yahoo</span>
                                <span class="article-sentiment positive">
                                    0.94
                                </span>
                            </div>
                            <div class="article-summary">Immunovant (IMVT) reported "encouraging" data from its study of batoclimab to treat uncontrolled Gra...</div>
                        </div>
                    </div>
            
                    <div class="article-card positive">
                        <div class="article-content">
                            <h3 class="article-title">
                                <a href="https://finnhub.io/api/news?id=0e3340e454f59d6000baa34808fd8de3afd5a706dc9a75f5830fadf526543a32" target="_blank" rel="noopener noreferrer">Roivant Sciences (ROIV) Announces Q1 2025 Business Update</a>
                            </h3>
                            <div class="article-meta">
                                <span>2025-08-29</span>
                                <span>Yahoo</span>
                                <span class="article-sentiment positive">
                                    0.40
                                </span>
                            </div>
                            <div class="article-summary">Roivant Sciences Ltd (NASDAQ:ROIV) is one of the Best Mid Cap Growth Stocks to Buy According to Hedge Funds. On August 11, Roivant Sciences Ltd (NASDAQ:ROIV) reported its financial and business update...</div>
                        </div>
                    </div>
            
                    <div class="article-card neutral">
                        <div class="article-content">
                            <h3 class="article-title">
                                <a href="https://finnhub.io/api/news?id=56f04f04a1a85cd2b1e51e32ef9aec7715f0d5031f48f8a6848119e17127b124" target="_blank" rel="noopener noreferrer">Roivant Sciences: Vant Model And IMVT-1402 Create A 2025 Catalyst Stack</a>
                            </h3>
                            <div class="article-meta">
                                <span>2025-08-15</span>
                                <span>SeekingAlpha</span>
                                <span class="article-sentiment neutral">
                                    0.00
                                </span>
                            </div>
                            <div class="article-summary">Roivant Sciences Ltd.'s Vant model offers risk-isolated growth and monetization flexibility. Click for key ROIV drivers including Brepocitinib's Phase 3 potential....</div>
                        </div>
                    </div>
            
                    <div class="article-card neutral">
                        <div class="article-content">
                            <h3 class="article-title">
                                <a href="https://finnhub.io/api/news?id=c58aead35f0dafa52fddb4ad3b93042fa24908861b6cf82c8d3119ff61cb388d" target="_blank" rel="noopener noreferrer">Immunovant's Q1 Loss Narrower Than Expected, Pipeline in Focus</a>
                            </h3>
                            <div class="article-meta">
                                <span>2025-08-12</span>
                                <span>Yahoo</span>
                                <span class="article-sentiment neutral">
                                    0.06
                                </span>
                            </div>
                            <div class="article-summary">IMVT reports a narrower Q1 loss, as spotlight remains on IMVT-1402's broad clinical potential across multiple indications....</div>
                        </div>
                    </div>
            
                    <div class="article-card positive">
                        <div class="article-content">
                            <h3 class="article-title">
                                <a href="https://finnhub.io/api/news?id=3e92d739db69e055866ee6ee71751a22f13af359c0ef8680675771bdfe742c49" target="_blank" rel="noopener noreferrer">Immunovant Provides Corporate Updates and Reports Financial Results for the Quarter Ended June 30, 2025</a>
                            </h3>
                            <div class="article-meta">
                                <span>2025-08-11</span>
                                <span>Yahoo</span>
                                <span class="article-sentiment positive">
                                    0.44
                                </span>
                            </div>
                            <div class="article-summary">Initiated a second potentially registrational study of IMVT-1402 in Graves‚Äô disease (GD) and a potentially registrational study of IMVT-1402 in Sj√∂gren‚Äôs disease (SjD), both in June 2025All other clin...</div>
                        </div>
                    </div>
            
                </div>
            </div>
        </body>
        </html>
        